李进 主任医师，教授
硕士招生类型：学术型；专业型
硕士招生专业：肿瘤学
博士招生类型：学术型；专业型
博士招生专业：肿瘤学
所在院系：附属东方医院
联系方式：lijin@csco.org.cn
课题组链接：
研究方向
主要任职
科研业绩
1.恶性肿瘤（胃肠肿瘤）的内科治疗
2.晚期肿瘤分子靶向治疗及免疫治疗
3.新药I期临床研究
国家级学会任职：
中国临床肿瘤学会（CSCO）理事长
Presidentof Chinese Society of Clinical Oncology(CSCO)
亚洲肿瘤学联盟（FACO)主席
Presidentof Federation of Asian Clinical Oncology (FACO)
亚洲肿瘤分子靶向治疗继续教育委员会（MTTC）常委
Standingcommittee member of Medical Education Workshop on Molecular Targeted Therapy ofCancer (MTTC)
中国医师学会结直肠癌专业委员会副主任委员
Vicechairman of Chinese medical doctor association colorectal cancer group
中国临床肿瘤学会药物安全专家委员会主任委员
Chairmanof Anti-cancerdrug Safety Management Committee (ASMC)
上海市抗癌协会胃肠肿瘤专业委员会副主任委员
Vicechairman of Shanghai Anti-cancer Association GI group
学术杂志编委：
《CancerScience》 副主编
Associateeditor of
《Journalof Colorectal Cancer》中文版 副主编
Associateeditor of < Journal of Colorectal Cancer> (Chinese version)
《中华肿瘤杂志》 编委
Editorof
《癌症》 责任编委
Editorof
《中国癌症杂志》 编委
Editorof
《临床肿瘤学杂志》 副主编
Associateeditor of < Chinese Clinical Oncology>
《Journalof Colorectal Cancer》中文版 副主编
Associateeditor of
《Journalof Hematology and Oncology》 编委
Editorof < Journal of Hematology and Oncology>
《ClinicalCancer Drugs》 编委
Editorof < Clinical Cancer Drugs>
近三年所有科研项目：
1. 科技部非传染性疾病防控研究（2017YFC**），胃癌靶向治疗新技术研究-靶向药物治疗胃癌的早期临床研究及多中心大样本临床研究；项目来源：中华人民共和国科技部；起止年月：2017.07-2020.12；资助金额：770万；
2017.07-2020.12 Title: targeted treatmentfor gastric cancer: early clinical trial and multi-center clinical trial
Grant NO.: 2017YFC** (￥7,700,000)
Major goal: to find new effective targetfor gastric cancer treament and investigate new drug for gastric cancer.
2. 复发转移大肠癌的治疗新策略（2016ZX-07-003）；项目来源：国家卫生计生委医药卫生科技发展研究中心；起止年月：2016.11-2018.12；资助金额：1000万；
2016.11-2018.12 Title: new strategy formetastatic colorectal cancer
Grant NO.: 2016ZX-07-003 (￥10,000,000)
Major goal: to find new strategies formCRC, especially targeted therapy and immunotherapy.
3. 基于外显子测序技术筛选胃癌复发转移新基因CDH4突变及其功能研究；项目来源：国家自然科学基金；起止年月：2018.01-2020.12；资助金额：55万；
2018.01-2020.12 Title: role of CDH4mutation in grastric cancer recurrence based on whole exome sequence
Grant NO.: 2016ZX-07-003 (￥10,000,000)
Major goal: to investigate the role ofCDH4 mutation in gastric cancer recurrence, and possible mechanism.
4. 国际标准抗肿瘤新药临床试验平台建设（2012ZX09303-018-002）；项目来源：国家十二五重大攻关计划课题；起止年月：2012.01-2017.12；资助金额：1400万。
2012.01-2017.12 Title: establishment ofinternational standardized new platform for anti-cancer drug clinical trial.
Grant NO.: 2012ZX09303-018-002(￥14,000,000)
Major goal: to establish new platform fornew drug clinical trial.
近三年获奖成果：
1. 2014年“胃癌发生发展的分子机制研究与临床治疗新策略的建立和应用《国家教育部科技进步》二等奖。（排名第1）
2014 Ministry of Education Prize forProgress in Science and Technology, second award (No. 1).
2. 2016年结直肠癌个体化治疗策略创新与应用《国家科技进步奖》二等奖 (排名第3)
2016 National Prize for Progress inScience and Technology, second award (No. 3).
近三年发表论著(第一作者或通讯作者）：
[1] Li J, Qin SK, et al. Effect ofFruquintinib vs Placebo on Overall Survival in Patients With Previously TreatedMetastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018Jun 26;319(24):2486-2496.
[2] Li J, Xu R, Xu J, et al. Phase IIstudy of S-1 plus leucovorin in patients with metastatic colorectal cancer:Regimen of 1 week on, 1 week off. Cancer Sci. 2017 Oct;108(10):2045-2051.
[3] Zheng PP, Li J, KrosJM.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Criticalresearch-practice gaps, challenges, and insights. Med Res Rev. 2018Jan;38(1):325-376.
[4] Liu x, Zhang X, Li J, et al.Plasma microRNA-based signatures to predict 3-year postoperative recurrencerisk for stage II and III gastric cancer. Int J Cancer. 2017 Nov15;141(10):2093-2102.
[5] Lin F, Dai C, Ge X, Tang W, LinY, Wang Y, Li J. Prognostic significance and functional implication of immuneactivating receptor NKG2D in gastric cancer. Biochem Biophys Res Commun. 2017Jun 3;487(3):619-624.
[6] Xu RH, Li J, Bai Y, et al. Safetyand efficacy of fruquintinib in patients with previously treated metastaticcolorectal cancer: a phase Ib study and a randomized double-blind phase IIstudy. J Hematol Oncol. 2017 Jan 19;10(1):22.
[7] Cao J, Zhang J, Peng W, Chen Z,Fan S, Su W, Li K, Li J. A Phase I study of safety and pharmacokinetics offruquintinib, a novel selective inhibitor of vascular endothelial growth factorreceptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solidtumors. Cancer Chemother Pharmacol. 2016 Aug;78(2):259-69.
[8] Li J, Qin S, Xu J, et al.Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib inPatients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma ofthe Stomach or Gastroesophageal Junction. J Clin Oncol. 2016 May1;34(13):1448-54.
[9] Wang C, Guo W, Zhou M, Zhu X, JiD, Li W, Liu X, Tao Z, Zhang X, Zhang Y, Li J. The Predictive and PrognosticValue of Early Metabolic Response Assessed by Positron Emission Tomography inAdvanced Gastric Cancer Treated with Chemotherapy. Clin Cancer Res. 2016 Apr1;22(7):1603-10.
[10] Li J, Qin S, Xu R, et al.Regorafenib plus best supportive care versus placebo plus best supportive carein Asian patients with previously treated metastatic colorectal cancer(CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. LancetOncol. 2015 Jun;16(6):619-29.
[11]Chen Z, Guo W, Cao J, Lv F, Zhang W, Qiu L, Li W, Ji D, Zhang S, Xia Z, Wang J,Li J. Endostar in combination with modified FOLFOX6 as an initial therapy inadvanced colorectal cancer patients: a phase I clinical trial. Cancer ChemotherPharmacol. 2015 Mar;75(3):547-57.
